Entities

Core Eqty is an Oslo investment manager backing Nordic B2B software and hardware-enabled technology companies with proven products and international growth ambitions. Its team has built and scaled technology businesses and works alongside portfolio companies on product development, sales, marketing and expansion into global markets. Its first fund targets growth-stage companies whose technologies improve efficiency and sustainability, including railway AI, wireless sensing and industrial software. The manager operates through Core Eqty AS, established in 2023.

Jake Yount is a managing principal at Echo Health Advisors. He previously worked at Blue Cross NC in finance, product development, provider payment and healthcare operations. He holds an East Carolina MBA.

David Weir is an executive assistant with Echo Health Advisors, based in Seattle. He also serves as board secretary for Portland’s Triangle Productions theatre company.

Annika Van Gilder is a senior associate at Echo Health Advisors. Her earlier work includes Arc Health, global health research funding and behavioral health initiatives. She holds a Michigan Ross MBA.

Ralph Sabin is a senior advisor to Echo’s strategic investment team. He co-founded Pacific Venture Group and previously held senior positions at Ernst & Young and Fortis Advisors.

Stephanie Leonard is an executive assistant at Echo Health Ventures, based in Seattle. She is also involved in the Pacific Northwest art and film community.

Amanda Johnson is a senior analyst in Echo’s legal and administration team. She previously worked in administration at a biotechnology company and as a corporate paralegal at Wyrick Robbins.

Jose Guerola is a principal in Echo’s strategic investment team. He previously invested at Johnson & Johnson’s investment arm and Carlyle and worked in Credit Suisse M&A. He holds a Wharton MBA.

David Goad is a senior associate in Echo’s strategic investment team. His earlier experience includes Cambia finance and corporate development in life sciences and education. He holds a Washington State MBA.

Dustin Duke is Echo Health Ventures’ controller. He previously worked in public accounting at BDO and Grant Thornton, including audits of investment businesses and life-sciences funds. He holds a CPA licence.

Bob Dolan is a managing principal at Echo Health Advisors. His healthcare leadership background includes The Partnership for a Healthy Arkansas, Life & Specialty Ventures and Saint Francis Heart Hospital.

Nash Carey-Ewend is a senior associate at Echo Health Advisors. He previously worked in business development and client relations at 3D-printing company Carbon and in technology deployment at UNC Health.

Misty Burgner directs operations and administration at Echo Health Ventures. She previously spent more than two decades at Blue Cross NC, including leadership in legal and administrative operations.

Taylor Auten is general counsel at Echo Health Ventures. He previously advised on investments and corporate transactions at Wyrick Robbins and Sullivan & Cromwell. He studied law at Duke and engineering at NC State.

Omair Ahmed is a principal in Echo’s strategic investment team and a current board observer at Scipher Medicine, Abacus Insights, Ideon and Vori Health. His earlier roles include Accenture Strategy, Merck’s investment fund and 7Wire Ventures.

Jessica A. Zeaske is a managing partner in Echo’s strategic investment team. She previously invested at GE Ventures and Lemhi Ventures. Her education includes Stanford, Johns Hopkins and Regis University.

Kurt Sheline is a strategic investment partner at Echo Health Ventures. His earlier roles include Cascade Asset Management, Cascadia Capital, Pathway Capital Management and Merrill Lynch. He holds a Berkeley MBA. Kurt Sheline is publicly listed by Thyme Care as Board Observer. The directory describes their outside affiliation as Partner, Echo Health Ventures; that title is context, not an executive position at Thyme Care.

Suzanne McLemore leads Echo Health Advisors as a managing partner. She previously directed technology partnerships at Cambia and worked in strategy and partnerships at IBM. She holds degrees from Columbia and Duke.

Troy Arnold is a partner in Echo Health Advisors. He previously worked in strategy, provider partnerships and value-based care at Blue Cross NC. He holds business and healthcare administration degrees from UNC and Minnesota.

Dusty Lieb leads investments at Echo Health Ventures. His background includes Cambia strategic investing and healthcare transactions at Harris Williams. He studied economics at the University of Pennsylvania.

Jon Eide is Echo Health Ventures’ managing partner and COO. He previously practised corporate law at Robinson Bradshaw and worked in banking and audit. He holds a Northwestern law degree and a CPA licence.

Rob Coppedge is CEO and a founder of Echo Health Ventures. He previously led Cambia Health Solutions’ diversified businesses and investment activities and was a partner at Capitol Health Partners.

Echo Health Ventures is a US strategic venture capital and growth equity investor founded in 2016 to help healthcare businesses expand. It manages investment and commercial collaboration for the Echo Innovation Alliance, whose members include Cambia Health Solutions, Blue Cross NC, USAble Corporation and BlueCross BlueShield of Tennessee. Led by CEO Rob Coppedge, its team combines investing, healthcare partnerships, legal and operational expertise. Relevant portfolio businesses include causal-AI drug-discovery company Aitia, behavioral-health analytics platform NeuroFlow, multiple-sclerosis precision-medicine company Octave Bioscience, conversational-AI provider mPulse, healthcare AI platform Optura, and precision-immunology company Scipher Medicine. Echo’s broader portfolio covers healthcare services and technology; AI or neuroscience relevance is evaluated for individual companies rather than assumed for every investment.

Skagerak Capital is a Norwegian venture and growth investment manager backing B2B software, AI and deep technology businesses with international growth potential and a positive environmental impact. It focuses on companies with proven customer demand and helps them scale through active ownership, operational support, board work and acquisitions. It also selectively backs industrial hardware and manages regional seed and growth funds for Agder, Innlandet, Telemark and Vestfold. Founded in 2006, the firm combines investment capital with commercial and technical expertise across Norwegian and Nordic markets.

Stellai is a Norwegian company building industrial computer-vision systems for waste and recycling facilities. Its AI co-pilot uses cameras mounted on material-handling equipment, or off-machine camera setups, to detect hazardous objects such as lithium batteries during pre-sorting and alert operators before they cause fires or contaminate processing streams. Its interface supports visual inspection, hazard alerts and customer traceability, while shared learning across installations helps improve detection. The company operates from Kristiansand and Lillestrøm.

Tunable is an Oslo-based deep-technology company developing compact, real-time multi-gas analysers using microelectromechanical systems, micro- and nanotechnology and infrared spectroscopy. Its programmable optical sensors turn gas composition and emissions into data for industrial process control, maritime fuel and emissions monitoring, and fresh-produce quality assessment. Its gas fingerprint recognition combines sensor data with machine learning to identify conditions such as fruit ripeness or spoilage. Founded in 2015, the company sells gas analysis systems designed for continuous operation in industrial environments.

Torsten Hombeck has served as Scipher Medicine’s interim chief financial officer since March 2026. His biotechnology finance career includes CFO roles at Akari Therapeutics, Aspira Women’s Health, Agennix and GPC Biotech, and executive positions at Promethera Biosciences and Cytonet. He holds an MBA and a doctorate in finance from EBS University of Business and Law in Germany.

Nysnø Climate Investments is the Norwegian state-owned investment company backing early-stage businesses and venture funds whose technologies can reduce greenhouse gas emissions. It makes commercial equity investments alongside private investors in climate and industrial technologies, including renewable energy, energy storage, hydrogen, digital infrastructure and AI-enabled resource efficiency. Established in 2017 and operational since 2018, it is headquartered in Stavanger with an Oslo office, and supports portfolio companies with investment expertise and active ownership. Its capital base and assets under management are distinct from a newly closed fixed-life venture fund.

SuperSeed is a London venture capital manager founded by Mads Jensen and Dan Bowyer in 2018. It invests at pre-seed and seed in B2B companies applying AI to industrial and commercial workflows, with an increasing focus on physical AI in manufacturing, construction, logistics, agriculture and energy, alongside frontier technologies such as space, quantum computing and fusion. Its team helps technical founders commercialise products, develop sales models, recruit and connect with customers. SuperSeed Ventures LLP manages the funds; the separately listed SuperSeed Capital investment vehicle is not the manager.

aMoon general partner and Scipher Medicine board director. Previously invested at Signet Healthcare Partners and Joddes and researched pharmaceutical equities at Morgan Stanley and Goldman Sachs. Todd Sone is published by aMoon as General Partner. Healthcare investor with experience in equity research and institutional investing; co-leads the Growth strategy. Todd Sone is a current Iantrek board member and is identified by the company as aMoon general partner. The issuer2025SeriesC announcement names aMoon as joining the round, without formally assigning co-lead status.

Scipher Medicine scientific co-founder and board director. Harvard physician-scientist and physician-in-chief emeritus at Brigham and Women's Hospital, with expertise in cardiovascular biology and network medicine.

Scipher Medicine senior vice president for network medicine and data science. A physicist trained in the Barabasi laboratory, working on the Spectra platform, biomarker discovery and therapeutic target identification.

Scipher Medicine board director and biotechnology adviser with experience in investment banking, corporate finance, mergers and acquisitions.

Scipher Medicine chief business officer, as listed in its current leadership directory.

Scipher Medicine strategic partnership consultant with experience in cross-border licensing, alliances and technology transfer, including work at Ardelyx, Acucela and Peninsula Pharmaceuticals.

Scipher Medicine consultant for strategic partnerships and precision medicine. Previously worked in diagnostic product strategy and partnerships at QIAGEN, AstraZeneca, Quest, Paige.AI, Nuclea.AI and OMAPiX.

Scipher Medicine senior director of business development; named in the current public directory.

Scipher Medicine scientific co-founder and director. Network scientist at Northeastern University and Harvard Medical School researching complex systems and network medicine.

Scipher Medicine chief operating officer with experience in precision medicine, product development and clinical operations. Previously held leadership roles at Aspira, CareDx and Kaiser Permanente.

Scipher Medicine president, CEO and board director. Previously led CareDx and worked in strategy, partnerships and portfolio development at Ardelyx, AstraZeneca and other pharmaceutical companies; trained as a physician-scientist.

Blue Owl Healthcare Opportunities managing director and Scipher Medicine board director. Previously co-founded Cowen Healthcare Investments and worked in biotechnology investment banking.

Hive Autonomy develops physical-AI technology that allows existing industrial machines to operate autonomously under human supervision. Its platform combines machine sensing, decision-making and fleet coordination for equipment such as wheel loaders and forklifts, with deployments in construction, logistics and industrial production. Operators supervise machines and handle exceptions from a safe location. The company works in Norway and the United Kingdom and is expanding internationally. Its Norwegian legal entity was incorporated in August 2022.

Minerva Humanoids is a robotics company developing semi-autonomous humanoid robots for hazardous industrial and public-safety work. Its Roger robot allows specialists to perform manipulation tasks through remote operation using a virtual-reality headset, while its AI control system manages balance, navigation and fall recovery. The company targets dangerous energy-site operations and hazardous-material response, with trained operators retaining control of critical actions. Founded in late 2025, it is advancing prototypes and paid pilots from a San Francisco headquarters and offices in Massachusetts and Germany.

RunwayVC is a Norwegian venture capital manager investing from pre-seed through Series A in industrial technology companies. Operated by RunwayFBU Fund Management AS, it backs industrial AI and software, connectivity, robotics, automation and autonomous systems, primarily in Norway and the Nordics with selected investments elsewhere in Europe and the United States. It helps founders validate technology with industrial customers and gain access to technical expertise, pilots and commercial partners through the RunwayFBU ecosystem at Fornebu.

Laurion Capital Management partner since 2017, also known as Jerry Zhou. Develops quantitative and quantitative-informed discretionary strategies and leads biotechnology investing. Holds a Tsinghua biological sciences degree and a Harvard doctorate in biochemistry and molecular pharmacology.

Laurion Capital Management co-founder and founding partner, sharing responsibility for capital allocation, strategy development and risk management. Previously worked in JPMorgan equity derivatives and proprietary trading; holds a Princeton computer science degree.

Laurion Capital Management co-founder and founding partner. Previously a JPMorgan managing director in equity derivatives, overseeing structured options and proprietary quantitative equity-arbitrage and volatility strategies. Holds a Harvard economics degree.

Laurion Capital Management is a New York investment firm founded in September 2005 by Ben Smith and Sheehan Maduraperuma, former JPMorgan equity derivatives and proprietary trading colleagues. It combines quantitative and qualitative research across asset classes. Zhe (Jerry) Zhou became a partner in 2017 and leads its biotechnology investment strategies, bringing a background in biological sciences, biochemistry and molecular pharmacology. Its verified investments include Recursion's AI-enabled drug discovery platform, Exscientia's AI drug design, Scipher Medicine's precision immunology, Synthego's genome-engineering tools, TRexBio's computational immunobiology and Compass Pathways' mental-health therapeutics. These investments establish relevance to AI, deep technology and neuroscience, alongside the firm's broader capital-markets activities. Its public leadership directory names three partners; it does not publish a complete employee roster or venture-style portfolio catalogue.

Delos Capital operations manager since 2022, based in Taipei. Previously worked in education and instruction; holds a degree from National Chung Hsing University and completed law extension courses at National Taiwan University.

Delos Capital financial controller since 2018, responsible for accounting, tax, reporting and compliance in Hong Kong. Previously worked in finance and corporate tax at Bank of America Merrill Lynch and at Ernst & Young; a certified accountant.

Delos Capital executive assistant in Hong Kong since 2022. Previously worked in Nan Fung Group's corporate legal department and studied professional English communications at City University of Hong Kong.

Delos Capital office manager since June 2024, supporting its Boston-area operations. Previously worked in finance and operations at a technology company; holds an international relations degree from Saint Anselm College.

Delos Capital Hong Kong office manager since 2015. Previously managed office and executive support at Permira and worked in Goldman Sachs Asia investment banking administration.

Delos Capital managing director since 2024. Previously invested at Leaps by Bayer, founded a genomic diagnostic company while at RA Capital and worked on transactions at Moderna. Also teaches bio-innovation; based in Cambridge.

Delos Capital associate since 2022. Previously researched drug targets and autoimmune disease at Boehringer Ingelheim; holds a genetics doctorate from Rochester and a biology degree from Xiamen University. Based in Hong Kong.

Delos Capital partner since 2024. Previously an operating partner at Flagship Pioneering, COO of Laronde and a Moderna executive overseeing clinical programs and manufacturing. Earlier worked at McKinsey and Merck; based in Cambridge.

Delos Capital founder and managing partner since 2014. Previously a partner and Asia co-head at Permira, a Goldman Sachs managing director and a corporate finance lawyer at Davis Polk. Also co-founded Curamir and Tulavi; based in Hong Kong.

Cartesian is a Trondheim energy technology company designing and producing compact thermal batteries for heating and cooling. Its Thermal Box uses phase-change materials to store thermal energy and release it when demand or electricity prices rise. The modular systems integrate with building and industrial heating, ventilation and cooling installations, supporting load shifting and additional thermal capacity. The company commercialises research from SINTEF and NTNU and works with contractors, energy service companies and utilities across Europe.

Mia Health is a Trondheim health technology company offering a mobile app that converts heart-rate and activity data from wearable devices into personalised activity scores and fitness-age estimates. Built around exercise research from NTNU and technology from SINTEF, it helps individuals and employers understand physical activity patterns and set activity goals. Its AQ score summarises activity over seven days, alongside guidance and health-trend insights. The Norwegian legal entity was established in 2016; the Mia Health app launched in April 2023.

Sonair is an Oslo deep-tech company developing ultrasonic sensors that give autonomous robots a three-dimensional view of people and obstacles. Its ADAR sensor uses acoustic detection and ranging in air, drawing on SINTEF research in ultrasound and micro-electromechanical systems. The company sells sensors for mobile robots and industrial automation, including environments where lighting conditions, dust or transparent surfaces challenge conventional sensing. Its commercial ADAR product launched in 2025, and its current ADAR One is designed and certified for functional safety.

Oxford gastroenterologist and immunologist, and TRexBio scientific founder. Researches intestinal immune biology, inflammatory bowel disease and the cellular organization of inflamed tissue.

Johns Hopkins immunologist and TRexBio scientific founder. Directs cancer immunotherapy research focused on T-cell biology, cancer vaccines and immune regulation.

UCSF pharmaceutical chemistry professor and TRexBio scientific founder, also known as James Wells. Researches protein engineering and molecular tools for inflammation and cancer; founded the UCSF Small Molecule Discovery Center and Sunesis Pharmaceuticals.

UCSF dermatologist, skin immunologist and TRexBio scientific co-founder. Studies immune regulation in tissues and development of therapies targeting regulatory T cells; also co-founded Sitryx and Delinia.

UCSF dermatologist and TRexBio scientific founder. Leads research on psoriasis and inflammatory skin disease, using genetics, functional genomics, tissue biobanks and single-cell profiling.

UCSF oncologist and TRexBio scientific founder focused on melanoma, immunotherapy and early clinical trials. Trained in medicine, internal medicine and hematology-oncology.

TRexBio scientific founder and physician-scientist with experience building biotechnology companies and investing in life sciences. Research interests include metabolic disease and novel therapeutic development.

SV Health Investors senior partner and TRexBio director, also known as Mike Ross. Previously founded and led Arris Pharmaceutical and MetaXen and worked in scientific leadership at Genentech.

SV Health Investors managing partner since January 2024, having joined in 2022. Previously a Pfizer Ventures partner through December 2021. TRexBio director since May 2019, with resignation planned before IPO registration effectiveness; trained in biochemistry and molecular biophysics.

Alexandria Real Estate Equities founder and executive chairman, and founder of Alexandria Venture Investments. TRexBio director since November 2024; has experience in life sciences real estate, venture investing and corporate finance. Current Alexandria primary affiliation: founder and continuing leader of Alexandria Venture Investments, a corporate venture platform established in 1996. He is the parent’s Executive Chairman and Founder; earlier Chairman, CEO and President tenure ended April 2018. His prior legal career focused on corporate finance, venture investments and mergers, with earlier CPA and tax work; he holds UCLA undergraduate and JD degrees. This institution-level affiliation does not imply a personal cash check.

Biotechnology entrepreneur and TRexBio director. Co-founded Plexxikon and previously served as its CEO; also founded Sugen and worked at Boehringer Mannheim. Trained in molecular genetics at Heidelberg.

Eli Lilly vice president and global head of Lilly Gateway Labs, and TRexBio director. Has held scientific and leadership roles in research and drug development; trained in membrane biophysics and drug transport. Julie Gilmore leads Lilly Gateway Labs and Catalyze360 portfolio management as vice president and global head. Her Lilly career spans research, scientific communications, European clinical operations and neurodegeneration/pain portfolio management. She trained in membrane biophysics at Purdue and drug transport at Indiana University.

Polaris Partners partner focused on early-stage biotechnology and healthcare. Previously conducted research at Inzen Therapeutics and Vertex; holds a Harvard chemical biology doctorate. TRexBio director as of October 5, 2026, with resignation planned immediately before IPO registration effectiveness. BeMe’s2021issuer announcement names her among its board members and advisors. That collective description does not assign an individual director seat; recorded affiliation remains qualified and historical after acquisition. Polaris managing partner in New York, focused on early biotechnology and healthcare investing. Joined in2019. Her current manager biography includes boards of EpiBiologics, TRexBio, Auron, Amplifire and SunBird Bio; older company affiliations retain their own date qualifications.

Immunocore CFO and head of corporate development, and TRexBio director. Previously spent two decades at Eli Lilly in finance, investor relations, transactions and business development.

TRexBio lead independent director since October 2026, following service as executive chair and board chair. Former Calistoga Pharmaceuticals CEO and former NEA partner and adviser, with experience in drug development, commercial strategy and biotechnology finance.

TRexBio vice president and head of translational medicine. Previously spent 18 years at Genentech working on disease mechanisms, biomarker discovery and clinical implementation; trained at Imperial College London, Cambridge and Harvard.

TRexBio vice president of clinical operations with experience managing early clinical studies, compliance and inspection readiness. Previously held clinical operations roles at ImmPACT Bio, PACT Pharma and PUMA Biotechnology.

TRexBio chief scientific officer overseeing target discovery, validation and translation. Previously held research leadership roles at Genentech; trained in immunology at Toronto and conducted postdoctoral research at Harvard.

TRexBio head of portfolio and alliance management. Previously led new product planning and commercial programs at Ultragenyx and held strategy, portfolio and brand-management roles at Genentech.

TRexBio chief medical officer with clinical-development experience in autoimmune and inflammatory disease. Previously worked at Biora Therapeutics, Human Immunology Biosciences and Genentech/Roche and practiced rheumatology at Stanford.

TRexBio chief financial officer. Previously CFO of Applied Molecular Transport and held finance and operating roles at Singulex, Novartis Vaccines & Diagnostics and Genentech.

TRexBio CEO and, since October 2026, board chair. Previously spent 36 years at Eli Lilly, including leading clinical development teams and Lilly New Ventures before retiring from Lilly in 2021.

TRexBio chief operating officer with experience in business development, corporate transactions, investor relations and operations. Previously led business development and investor relations at Myovant Sciences and worked in Roche Pharma Partnering; trained as an attorney.

TRexBio is a South San Francisco clinical-stage biotechnology company developing medicines that act on tissue regulatory T cells to restore immune balance and support tissue repair in autoimmune and inflammatory disease. Its Deep Biology platform combines human tissue samples, single-cell gene-expression mapping, computational biology and functional genomics to discover and validate therapeutic targets. The company's pipeline includes TNFR2 agonist TRB-061 in clinical development for atopic dermatitis and additional tissue-directed immunoregulatory programs. Founded and seed funded by SV Health Investors in 2018, it announced a USD59 million Series A in June 2021, increased to USD85 million after a March 2022 extension. Its USD84 million Series B announced in November 2024 was funded in two closings in November 2024 and March 2025; a separate USD50 million Series B extension closed in January 2026. Johnston Erwin is CEO and became board chair in October 2026, with Carol Gallagher serving as lead independent director. Six directors have announced resignations immediately before IPO registration effectiveness. An IPO registration was pending as of this review; proposed IPO proceeds are not recorded as completed financing.

Previse Technologies is a Norwegian SINTEF spin-out developing predictive maintenance software for corrosion under insulation in industrial pipes. It combines humidity-sensor data, physics-based simulation of water movement and statistical analysis to identify areas most likely to require maintenance. The platform can integrate sensors from different suppliers and run in cloud or on-premises environments. Its aim is to help process-plant operators target inspections and maintenance while reducing unnecessary insulation removal, waste and safety risks.

SINTEF Venture is the seed and early-stage investment operation of SINTEF TTO, the Norwegian research institute’s technology commercialisation company. It develops companies around research from SINTEF, supplies venture capital and helps founders bring scientific technology to market. Its portfolio spans medical devices, ultrasound imaging, industrial robotics, sensors, energy systems and environmental software. The manager operates a series of venture funds and works with external investors and research teams as companies progress from pre-seed development into commercial growth.

SonoClear is a Trondheim medical technology company developing an acoustic coupling fluid for ultrasound-guided brain surgery. Its SonoClear System is designed to match the ultrasound properties of healthy tissue and reduce imaging artefacts introduced during tumour resection, helping neurosurgeons assess tumour borders. The company originated from collaboration among SINTEF, NTNU and St Olav’s Hospital and is conducting clinical investigations. Its system remains under development, exclusively for investigational use, and is not approved for sale in any geography.

Microbiologist with experience in research, commercialization of biotechnology and medical projects, management and board service.

Norwegian finance and biotechnology executive with an NHH MSc and UC Berkeley PhD. Own website identifies CFO; government register retains the separate legal general-manager role.

Alex Therapeutics is a Stockholm digital health company developing therapy companion apps with pharmaceutical partners. It combines cognitive behavioural therapy, patient-centred design and artificial intelligence to support medication adherence, behaviour change and disease-related mental health needs, particularly in rare diseases and oncology. Its products include Almee, a digital anxiety intervention studied in pulmonary fibrosis, and Levilog, a Parkinson’s medication companion app launched with Navamedic in the Nordics in 2025. The company builds indication-specific software and supports its clinical validation and regulated deployment.

Nisonic is a Trondheim medical software company developing non-invasive assessment of intracranial pressure using ultrasound and machine learning. Its FAST-ICP software automatically analyses transorbital images of the optic nerve sheath, measures image-derived biomarkers and guides probe positioning. A SINTEF spin-out, it works with neurosurgeons and clinical researchers to validate these methods in patients with brain injuries and other neurological conditions. Its current FAST-ICP software is for research use, with clinical studies underway in Europe, Africa and the United States.

Patient navigator at myTomorrows, identified in its 2026 media coverage of caregiver participation in clinical trials.

CTO of myTomorrows, leading AI adoption and technology strategy. Previously led enterprise engineering at Miro and the AWS development center in the Netherlands.

Senior site manager at myTomorrows, identified in its 2026 media coverage of Parkinson’s disease biomarkers.

COO of myTomorrows, overseeing global operations and stakeholder engagement. Previously COO at Ade Health and a commercial leader at Bayer Pharmaceuticals.

Director of partnerships development at myTomorrows, listed in its public expert directory.

Physician who founded myTomorrows in 2012. Previously held executive roles at Crucell and co-founded Leyden Labs.

Product manager and pharmacist at myTomorrows, listed as a company expert on patient access and healthcare technology.

Chief commercial officer of myTomorrows, leading global commercial strategy and pre-approval treatment access partnerships. Has extensive European biotechnology industry experience.

Head of pharma partnerships and customer success at myTomorrows, listed in its public expert directory.

Physician and CEO of myTomorrows. Trained in medicine and economics at the University of Amsterdam, with prior oncology clinical and research experience.

Avego Healthcare Capital is Avego's private equity strategy for commercial-stage healthcare businesses. It invests in specialty pharmaceuticals, pharmaceutical services, life sciences tools, over-the-counter products and medical devices, combining growth capital with operating experience and company-building support. The strategy shares the Avego group's offices in Alpharetta, Georgia, and New York. Its Fund II was formed in 2022; SEC disclosures identify Bala Venkataraman as manager of the general partner, James Flexner and Thomas Vandervort as managing partners, Kevin McNeill as partner and Alyssa Romano as fund CFO. All five remain listed in Avego's public group team directory. In November 2025, Avego Healthcare Capital Fund II invested EUR25 million in myTomorrows, an AI-enabled treatment-access platform. This private equity strategy is distinct from Avego BioScience Capital's therapeutics venture strategy and Velan Capital's public equities strategy.

Catalyze Capital is an Amsterdam-based venture investor backing European early-stage and academic spin-off companies in life sciences, sustainable technologies and deep tech. It invests at seed and Series A and helps founders with commercial strategy, intellectual property, licensing, follow-on financing and access to non-dilutive funding. The fund operates within Catalyze Group and works with its innovation consultancy on sourcing, due diligence and portfolio support. Its investments include AI-assisted epilepsy monitoring, retinal drug development and precision-fermentation fats.

Hadean Ventures is a European venture capital manager investing in life-science companies developing medicines, medical devices, diagnostics and digital health products. From offices in Oslo and Stockholm, it focuses particularly on the Nordic region and German-speaking Europe and supports companies across development stages. Its portfolio includes seizure monitoring using artificial intelligence, neurological drug discovery and digital mental-health treatments. Its investment team combines scientific expertise, venture investing and operational experience.

Kasvu Therapeutics is a Helsinki biotechnology company developing small-molecule medicines for neuropsychiatric and neurodegenerative disorders. Its lead programme KTX-0141 positively modulates the TrkB receptor to enhance neuroplasticity without engaging the serotonin receptor associated with psychedelic hallucinations. Originating from University of Helsinki research, the company is conducting studies needed before human trials and plans clinical development in major depressive disorder. Its drug candidates remain investigational; reported activity and safety findings are preclinical.

Early-stage technology investor experienced in research spinout co-creation, investment, governance, and team building across materials, quantum chemistry, and cancer therapies.

Has been an Alto director since August 2025. Previously chief medical officer at Cerevel and a clinical development leader at Otsuka and Avanir. His current Alto biography also identifies a senior adviser role at Bain Capital Life Sciences and a Rapport board role.

Avego senior advisor with pharmaceutical research, clinical-development and regulatory experience. Previously led AGI Therapeutics and Athpharma and held scientific leadership roles at Horizon, Vidara and Elan.

Avego operating partner and neurologist with biotechnology company-building experience. Co-founded Vidara Therapeutics and previously helped develop epilepsy therapies at UCB and Xcel Pharmaceuticals.

Avego office manager and executive assistant who joined in 2022. Previously managed office operations at Gage Spencer and Fleming. Holds a business-management degree from the University of Tampa.

Avego assistant controller who joined in 2024. Previously worked at Interval Partners, Pura Vida Investments, One William Street Capital Management and AMG Funds.

Avego chief financial officer and chief compliance officer who joined in 2023. Previously held finance leadership roles at Pura Vida Investments and Arrowstreet Capital.

Avego director of finance who joined in 2022. Previously worked at ZMC Advisors and Ernst & Young. A certified public accountant with accounting and biomedical-science graduate training.

Avego senior associate who joined in 2024. Previously worked on healthcare investments and royalties at Marathon Asset Management and in banking at J.P. Morgan and Mizuho.

Avego vice president who joined in 2022. Previously a healthcare investment-banking associate at Nomura. Graduated from Emory with a degree in finance and accounting.

Avego principal who joined in 2024, focusing on biotechnology therapeutics. Previously worked at RA Capital, Pfizer and Memorial Sloan Kettering. Holds an immunology doctorate from Weill Cornell.

Velan Capital senior analyst who joined in 2023. Previously invested at Altium Capital and Iguana Healthcare and researched biotechnology at RBC. Holds a molecular-biology doctorate from Weill Cornell.

Avego principal who joined in 2021. Previously invested in healthcare at Signet Healthcare Partners and worked in healthcare investment banking at Nomura and Jefferies.

Avego BioScience Capital managing director who joined in 2024 after investing at Blue Owl/Cowen Healthcare Opportunities and Roivant. TRexBio director since November 2024, with resignation planned before IPO registration effectiveness.

Avego partner who joined in 2018. Previously a vice president at Leerink Partners and a healthcare investment banker at Lazard. Holds a business-administration degree from UNC Chapel Hill.

Avego partner who joined in 2021. Previously chief business officer at Iveric bio and president of Amplitude Healthcare Acquisition Corporation. Earlier experience includes NPS Pharma, Genentech and Pfizer.

Avego partner and chief investment officer of its Velan Capital strategy. Previously a healthcare analyst at Broadfin, Iguana Healthcare and Pura Vida Investments, following medical-device operating roles.

Avego managing partner who joined in 2017. Previously invested in healthcare at Metalmark Capital and worked in healthcare investment banking at Morgan Stanley.

Avego managing partner who joined in 2015. Previously held pharmaceutical logistics, specialty pharmacy and business-development roles at DDN, Centric Health Resources, West-Ward and IGI Laboratories.

Avego founder and managing partner with experience building pharmaceutical companies. Previously co-founded Vidara Therapeutics and Alaven Pharmaceutical. Also identified as Balaji Venkataraman in SEC filings.

Avego is a healthcare investment firm founded in 2015 by former pharmaceutical entrepreneurs, with offices in Alpharetta, Georgia, and New York. Its three strategies cover commercial-stage private equity through Avego Healthcare Capital, therapeutics-focused venture capital through Avego BioScience Capital, and public healthcare equities through Velan Capital. The firm's investments span drug development, life sciences tools and healthcare services, including neuroscience and AI-enabled patient access. Bala Venkataraman is founder and managing partner; Thomas Vandervort and James Flexner are managing partners. Its public group directory lists investment professionals, finance and operations staff, an operating partner and a senior advisor. Avego provided growth equity in myTomorrows' USD29 million financing announced in November 2025.

Avego BioScience Capital is Avego's venture investment strategy for biotechnology companies at pivotal stages of therapeutic development. Its stated focus is mid-to-late-stage ventures in neurology, oncology, immunology, ophthalmology and rare disease, across biologics, small molecules and cell and gene therapies. It favors evidence-backed proprietary technologies and experienced drug-development teams. Publicly verified professionals include partner Vishal Kapoor, managing director Eric Pham and principal Christy Kuo; Bala Venkataraman manages the general partner, and Alyssa Romano holds finance and compliance leadership roles. Investments include MapLight Therapeutics, CellCentric and Memento Medicines. SEC filings identify the original Avego Bioscience Capital, L.P. vehicle, formed in 2021, and Avego BioScience Capital Fund II, L.P., formed in 2026. These are distinct funds within the strategy.

Neuro Event Labs is a Finnish medical technology company developing AI-assisted monitoring of epileptic seizures. Its Nelli system captures contact-free video and audio through a camera and microphone, uses machine learning to identify events indicative of motor seizures, and presents an interactive report for clinical review. The system supports monitoring at home and in hospitals and can include expert annotation services. Founded in Tampere in 2015, the company markets Nelli in Europe, the United Kingdom and the United States.

SHS Capital is a Tübingen-based private equity and growth investor specialising in healthcare. It invests in established companies and scale-ups across medical technology, pharmaceuticals, diagnostics and health technology, primarily in the DACH region, the Nordics and the Benelux. SHS takes minority and majority stakes and supports market access, reimbursement, commercialisation, acquisitions and international expansion. Its healthcare portfolio includes AI-assisted epilepsy monitoring, migraine neuromodulation and robotic rehabilitation.

Vascular-medicine specialist and an external healthcare expert affiliated with SHS Capital. Also listed by 415 Capital as a Senior Clinical Advisor. Both firms’ primary directories identify the same physician; these are advisory affiliations rather than firm employment.

FundaMental Pharma is a Heidelberg-based preclinical biotechnology company developing small-molecule medicines for treatment-resistant depression. Its lead candidate FMP374 is an orally bioavailable, dual-acting NMDA receptor modulator that disrupts the NMDAR/TRPM4 complex while also antagonising NMDA receptors. The company is preparing studies needed before human clinical development. Its research originated at Heidelberg University and also investigated approaches to glutamate-related neurodegeneration. The candidates remain investigational.

Thuja Capital is a Dutch early-stage life-science venture capital manager investing in European biotechnology, medical devices and healthcare innovation. It works with scientific founders and research institutions to translate discoveries into medicines and products, providing strategic, technical and operational support alongside capital. Its portfolio includes depression drug discovery, migraine neuromodulation, cancer immunotherapy and cardiovascular devices. Founded in 2007, the firm manages a series of healthcare funds and is based in Leiden.

Stellaromics director appointed February2026. Former president and chief executive of Expression Analysis and chief commercial officer of Fluidigm, with experience scaling genomics and diagnostics businesses.

Stellaromics scientific co-founder and adviser. MIT chemistry professor and Broad Institute core member researching spatial molecular biology, including STARmap and RIBOmap.

Stellaromics product development executive appointed May2026. Previously worked at Meso Scale Diagnostics, Qiagen, IsoPlexis and Quantum-Si on genomic and proteomic technologies.

Stellaromics commercial executive appointed May2026. Previously led commercial work at Abcam, Emulate, Berkeley Lights and Dovetail Genomics.

Stellaromics product management director working on genomics product commercialization and marketing.

Stellaromics human resources leader with experience advising and leading people teams.

Stellaromics computational biology and data science leader, working on machine-learning analysis pipelines and software.

Stellaromics chief technology officer with experience designing genomic sequencing platforms.

Stellaromics operations executive responsible for its operations leadership.

Genomics executive leading Stellaromics. Previously worked at Illumina and Bionano Genomics and led Cantata Bio; appointed president and chief executive in November2023.

Stellaromics is a Boston-based life sciences technology company founded in 2022 to develop three-dimensional spatial multi-omics tools. Its Pyxa platform combines sample preparation, automated volumetric confocal imaging, molecular assays, data analysis and visualization to study gene expression and protein synthesis in intact tissue. The technology builds on STARmap and RIBOmap research from scientific co-founders Karl Deisseroth and Xiao Wang, with applications in neuroscience, cancer and immunology. Pyxa entered commercial deployment in 2026, with installations announced at research institutions in the United States and Europe. Todd Dickinson leads the company, Ye Fu is co-founder and chief scientific officer, and Mark Pratt is chief technology officer. Its public leadership includes computational biology and machine-learning expertise. Stellaromics announced a USD25 million Series A in November 2023 and a USD80 million Series B in February 2025. MapLight Therapeutics also received equity in exchange for transferring a STARmap license in October 2023; this was noncash consideration rather than a cash financing round.

Carthera is a French clinical-stage medical device company developing ultrasound implants to improve delivery of medicines to the brain. Its SonoCloud device temporarily opens the blood-brain barrier using low-intensity ultrasound, and is being studied in brain cancers including glioblastoma and in neurodegenerative diseases. Founded in 2010 as a spin-off from Sorbonne University and AP-HP, the company develops and manufactures its devices and collaborates with clinical research institutions in Europe and the United States.

Diadem is an Italian diagnostics company researching blood-based biomarkers for early detection and prediction of Alzheimer’s disease and cognitive decline. Its AlzoSure Predict test uses a proprietary antibody targeting a specific conformation of the p53 protein, with the aim of supporting clinical assessment and recruitment for therapeutic trials. The company is conducting validation research and has operations in Italy, Germany and the United States. Its current website states that its tests are not approved in any geography.

Neuromod Devices is an Irish medical technology company developing and commercialising non-invasive neuromodulation for tinnitus. Its Lenire device combines customised sound delivered through headphones with mild electrical stimulation of the tongue to reduce tinnitus symptoms. Lenire received US FDA De Novo authorisation in 2023 and is offered through trained audiology and ENT clinics in the United States and Europe. The company conducts clinical and real-world research on bimodal stimulation and tinnitus care.

Salvia BioElectronics is a Dutch medical device company developing implantable neuromodulation for chronic migraine. Its investigational MySalvia Therapy uses two ultra-thin implants beneath the skin of the forehead and back of the head, activated on demand by an external wearable device to stimulate nerves linked to migraine. The company is conducting clinical studies and preparing regulatory submissions and commercialisation; the therapy has not yet been approved for commercial use. Salvia was founded in Eindhoven in 2017 and operates clinical activities internationally.

NMD Pharma nonexecutive director and INKEF General Partner, having joined INKEF in 2019. Earlier worked in genetics research and Sanofi strategy and business development. Holds a genetics doctorate and INSEAD MBA; no personal investment implied by his board role. Inkef’s current own directory independently lists Ivan Burkov as Partner; his sourced NMD Pharma biography identifies him as General Partner. His existing genetics doctorate, INSEAD MBA, Sanofi background, Salvia affiliation and authentic issuer portrait are preserved.

Le Dr. Jean-Pierre Bizzari est membre du conseil scientifique consultatif de l'Institut National du Cancer (INCa), membre du Board International de MATWIN et Président du « New Drug Advisory Committee » de l'Organisation Européenne pour la Recherche et le Traitement du Cancer (EORTC). Précédemment, le Dr. Bizzari était en charge du développement clinique en oncologie de grands groupes pharmaceutiques au niveau mondial. Il a notamment été Vice-Président Exécutif et Directeur du développement clinique en oncologie (États-Unis, Europe, Asie et Japon) de Celgene de 2008 à 2015. Le Dr. Bizzari a ainsi participé au développement clinique de plusieurs agents anti-cancéreux tels que Taxotere®, Eloxatin®, Abraxane®, Irinotecan® mais également le Gliadel® wafer pour le traitement du glioblastome. Il a publié plus de 70 articles dans des revues scientifiques de renom et présenté plus de 160 « abstracts » lors de congrès scientifiques, en particulier sur la méthodologie des essais cliniques et les analyses de pharmacocinétique et pharmacodynamique.. Jean-Pierre Bizzari est diplômé en médecine de l'Université de Nice, spécialisé en oncologie. Il a été interne à l'Hôpital de la Pitié-Salpêtrière à Paris puis à l'Ontario Cancer Institute et au Montreal Mac Gill Cancer Center au Canada.

Luca Condò is a Senior Investment Manager for CDP Venture Capital’s Evolution Fund, which backs innovative deep-technology businesses in SeriesA–B. His primary Diadem board biography describes corporate-finance work at EY and subsequent M&A and business-development positions at Recordati and Bracco Group. He holds a master’s degree in economics and business law from Bocconi University. The Diadem source and exact native manager portrait identify the existing LucaCondo person; his board affiliation is distinct from any personal investment.

Mitchel Berger is published by neuro42 as Advisor. The company describes this professional background: Neurosurgeon & Director of Brain Tumor Center, UCSF. External institution titles are directory background rather than independently verified new employment appointments.